Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 867

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 867
---
 field of activity in the US and German markets, which are not related to the company. Pursuant to the separation agreement signed between the parties on the same date, the loan provided by the Company to an IMC subsidiary under the aforementioned Memorandum of Understanding in the amount of USD $300 thousand will be repaid to the Company, including interest at an annual rate of 9% for the period outstanding, in 3 equal installments, the last of which will be transferred to the Company no later than July 31, 2024, including the accrued interest. As of the date of this Report, the Company has collected all payments in accordance with the separation agreement. c. Agreement with Pluri Inc. (NASDAQ: PLUR) On July 17, 2024, the Company entered into a collaboration agreement with Pluri Inc. (NASDAQ: PLUR) (hereinafter, “Pluri”), for the clinical manufacturing (outsourcing) of the Company’s products (hereinafter, the “Agreement”) at Pluri’s manufacturing facility, in accordance with the Company’s strategic plan. The Agreement for the manufacturing of the Company’s products constitutes a milestone in the development of the AstroRx ®product, as part of the Company’s preparation for a multi -centerphase IIA clinical trial, as well as in the development of the IsletRx product in support of the submission of the pre -INDtogether with iTolerance for the continuation of the development processes of the new treatment in the field of diabetes as part of the aforementioned collaboration and in preparation for the submission of an IND application in the future. Pursuant to the Agreement, the Company will grant Pluri the right to use the knowledge developed by the Company for

Annex G-60 KADIMASTEM LTD.
NOTES TO THE INTERIM FINANCIAL STATEMENTS NOTE 7: — EVENTS AFTER THE REPORTED PERIOD (cont.) the purpose of manufacturing the Company’s products by Pluri, with the first phase lasting up to 12 months, in consideration for a total of approximately USD $70 thousand, which will be paid in cash and/or by the issuance of the Company’s securities, as agreed by the parties. d. Board Approval of Mr. Ronen Twito Dual Role as CEO and Executive Chairman On October22, 2024, the Board decided that Mr.Twito would be appointed as the Company’s CEO, replacing Mr.Asaf Shiloni who completed his term as CEO on the same day. Mr.T